These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Manuscript SPR nucleocapsid_ChemRXiv.docx (962.87 kB)

A Rapid and Quantitative Serum Test for SARS-CoV-2 Antibodies with Portable Surface Plasmon Resonance Sensing

submitted on 13.04.2020, 17:07 and posted on 15.04.2020, 07:41 by Abdelhadi Djaileb, Benjamin Charron, Maryam Hojjat Jodaylami, Vincent Thibault, Julien Coutu, Keisean Stevenson, Simon Forest, Ludovic S. Live, Denis Boudreau, Joelle N. Pelletier, Jean-Francois Masson
We report a surface plasmon resonance (SPR) sensor detecting nucleocapsid antibodies specific against the novel coronavirus 2019 (SARS-CoV-2) in undiluted human serum. When exposed to SARS-CoV-2, the immune system responds by expressing antibodies at levels that can be detected and monitored to identify the patient population immunized against SARD-CoV-2 and support efforts to deploy a vaccine strategically. A SPR sensor coated with a peptide monolayer and functionalized with SARS-CoV-2 nucleocapsid recombinant protein detected anti-SARS-CoV-2 antibodies in the nanomolar range. This bioassay was performed on a portable SPR instrument in undiluted human serum and results were collected within 15 minutes of sample/sensor contact. This strategy paves the way to point-of-care and label-free rapid testing for antibodies.




Email Address of Submitting Author


Université de Montréal



ORCID For Submitting Author


Declaration of Conflict of Interest

J.-F.M., J.N.P. and L.S.L. have financial interest in Affinité Instruments